Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Prime Medicine, Inc. ( (PRME) ) has shared an update.
Prime Medicine, Inc. has updated its corporate presentation to reflect significant advancements in its gene editing programs. The company has initiated a Phase 1/2 trial for PM359 in CGD and is progressing with Wilson’s Disease and CF programs, leveraging strategic collaborations to expand their pipeline. The company aims to achieve clinical validation and sustainable value creation, supported by new partnerships and a strong financial position.
More about Prime Medicine, Inc.
Prime Medicine, Inc. is a company in the gene editing industry, focusing on the development of Prime Editing technology to provide curative treatments for genetic and non-genetic diseases. They are advancing their programs through strategic collaborations and partnerships, targeting diseases like chronic granulomatous disease (CGD), cystic fibrosis (CF), and Wilson’s Disease.
YTD Price Performance: -1.67%
Average Trading Volume: 1,147,555
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $385.6M
See more data about PRME stock on TipRanks’ Stock Analysis page.
